Skywater Technology: Sequencing Technology is Critical to Identify Mutations of the Virus

And Important for Epidemiologists When Tracking the Spread of Infections Through a Population Reports SkyWater Technology

Skywater Technology announced its partnership with MGI (a member of BGI Group) to supply critical components used by MGI’s DNA sequencing system DNBSEQ-T7, one of the first officially approved products by the National Medical Products Administration (NMPA – essentially China’s version of the FDA), under the emergency approval process for the coronavirus (COVID-19).

MGI, a global genomics platform company, along with its affiliates, was very quick to respond to the novel coronavirus virus and is bringing its full genomics expertise and resources to the front lines in the fight against it.

MGI has a manufacturing plant in Wuhan, China, the epicenter of the COVID-19 outbreak, where MGI delivered and deployed its NMPA-approved DNBSEQ-T7 sequencing systems for sequencing-based COVID-19 detection solutions.

SkyWater has been working with MGI for several years and supplies a component of BGI’s Flowcells (microfluidic MEMS devices). This component forms the basis for one of the consumables used in the sequencing kit in the DNBSEQ-T7 system, an ultra-high-throughput sequencing system manufactured by MGI.

At the time of this announcement, MGI is also providing automated sample preparation systems to help labs to increase the capacity to aid in more widespread and rapid screening in the U.S.

“As concerns rise about the coronavirus global pandemic, the pressure is on to enable even faster, more accessible testing. We are pleased to be working with genomics leader MGI and playing a role as a U.S. manufacturer in cutting-edge technology solutions that are making an important contribution to the detection of COVID-19,” said Thomas Sonderman, SkyWater President.

“Products from MGI and its affiliates are ready for international delivery to assist the global efforts in fighting the coronavirus pandemic, a number of which have already been sent to other countries,” said Dr. Yongwei Zhang, BGI Group VP & CEO, Americas Region. “SkyWater has been an excellent partner. We very much appreciate their support over the years, and we look forward to our ongoing partnership as we continue providing the highest quality genomic data at rapid turnaround times.”

SkyWater is certified to the ISO 13485 Quality Standard for Medical Devices to support the design, development and fabrication of DNA sequencing and other biochip applications in a wide range of emerging biomedical market segments.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version